The finding of significant differences in the 10-year survival rate between patients with ADAM6 HOM:DEL versus those with intact ADAM6 is of interest as this could potentially be used as a novel biomarker for monitoring the development and progression of BCP-ALL. This evidence concerns the gene ADAM6 and acute lymphoblastic leukemia.